Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 14:5:2320.
doi: 10.12688/f1000research.9283.1. eCollection 2016.

Epidemiology, virulence factors and management of the pneumococcus

Affiliations
Review

Epidemiology, virulence factors and management of the pneumococcus

Charles Feldman et al. F1000Res. .

Abstract

Pneumococcal infections continue to cause significant morbidity and mortality in patients throughout the world. This microorganism remains the most common bacterial cause of community-acquired pneumonia and is associated with a considerable burden of disease and health-care costs in both developed and developing countries. Emerging antibiotic resistance has been a concern because of its potential negative impact on the outcome of patients who receive standard antibiotic therapy. However, there have been substantial changes in the epidemiology of this pathogen in recent years, not least of which has been due to the use of pneumococcal conjugate vaccines in children, with subsequent herd protection in unvaccinated adults and children. Furthermore, much recent research has led to a better understanding of the virulence factors of this pathogen and their role in the pathogenesis of severe pneumococcal disease, including the cardiac complications, as well as the potential role of adjunctive therapy in the management of severely ill cases. This review will describe recent advances in our understanding of the epidemiology, virulence factors, and management of pneumococcal community-acquired pneumonia.

Keywords: Antibiotic resistance; Streptococcus pneumoniae; adjunctive therapy; community-acquired pneumonia.

PubMed Disclaimer

Conflict of interest statement

Charles Feldman has acted on the advisory board or speakers’ bureau (or both) of pharmaceutical companies manufacturing or marketing macrolide antibiotics and pneumococcal conjugate vaccines (Abbott, Aspen, Pfizer, and Sandoz). Ronald Anderson declares that he has no competing interests. Competing interests: Mathias Pletz has acted on the advisory board and/or speaker’s bureau of pharmaceutical companies manufacturing or marketing antibiotics and pneumococcal conjugate vaccines (Astrazeneca, Pfizer, Novartis, MSD, Basilea). No competing interests were disclosed.

References

    1. File TM, Jr, Marrie TJ: Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130–41. 10.3810/pgm.2010.03.2130 - DOI - PubMed
    1. Isturiz RE, Luna CM, Ramirez J: Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis. 2010;14(10):e852–6. 10.1016/j.ijid.2010.02.2262 - DOI - PubMed
    1. Shibl AM, Memish ZA, Ibrahim E, et al. : Burden of adult community-acquired pneumonia in the Middle East/North Africa region. Rev Med Microbiol. 2010;21(1):11–20. 10.1097/MRM.0b013e3283377af7 - DOI
    1. Song JH, Thamlikitkul V, Hsueh PR: Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011;38(2):108–17. 10.1016/j.ijantimicag.2011.02.017 - DOI - PubMed
    1. Welte T, Torres A, Nathwani D: Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–9. 10.1136/thx.2009.129502 - DOI - PubMed

LinkOut - more resources